132 related articles for article (PubMed ID: 26316891)
1. Loss of IRF8 Inhibits the Growth of Diffuse Large B-cell Lymphoma.
Xu Y; Jiang L; Fang J; Fang R; Morse HC; Ouyang G; Zhou JX
J Cancer; 2015; 6(10):953-61. PubMed ID: 26316891
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.
Zhong W; Xu X; Zhu Z; Du Q; Du H; Yang L; Ling Y; Xiong H; Li Q
Oncotarget; 2017 Jul; 8(30):49757-49772. PubMed ID: 28537908
[TBL] [Abstract][Full Text] [Related]
3. IRF8 is associated with germinal center B-cell-like type of diffuse large B-cell lymphoma and exceptionally involved in translocation t(14;16)(q32.33;q24.1).
Tinguely M; Thies S; Frigerio S; Reineke T; Korol D; Zimmermann DR
Leuk Lymphoma; 2014 Jan; 55(1):136-42. PubMed ID: 23573829
[TBL] [Abstract][Full Text] [Related]
4. IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma.
Elfrink S; Ter Beest M; Janssen L; Baltissen MP; Jansen PWTC; Kenyon AN; Steen RM; de Windt D; Hagemann PM; Hess C; van Spronsen DJ; Hoevenaars B; van der Spek E; Xu-Monette ZY; Young KH; Kaffa C; Bervoets S; van Heek J; Hesius E; de Winde CM; Vermeulen M; van den Brand M; Scheijen B; van Spriel AB
Blood Adv; 2022 Apr; 6(7):2254-2266. PubMed ID: 35086136
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
6. Different predictive values of interim
Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
[TBL] [Abstract][Full Text] [Related]
7. [Immunophenotypes and prognosis of diffuse large B-cell lymphoma: a study of 500 cases].
Luo DL; Liu YH; Zhuang HG; Li L; Xu FP; Zhang F; Luo XL; Xu J
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):235-9. PubMed ID: 21615996
[TBL] [Abstract][Full Text] [Related]
8. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
[TBL] [Abstract][Full Text] [Related]
9. The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries.
Shiozawa E; Yamochi-Onizuka T; Takimoto M; Ota H
Leuk Res; 2007 Nov; 31(11):1579-83. PubMed ID: 17448534
[TBL] [Abstract][Full Text] [Related]
10. [Immunohistochemical classification and prognosis of diffuse large B-cell lymphoma in China].
Chen Y; Xiao L; Zhu X; Lu C; Yu B; Fan D; Yin Y
Zhonghua Bing Li Xue Za Zhi; 2014 Jun; 43(6):383-8. PubMed ID: 25208988
[TBL] [Abstract][Full Text] [Related]
11. A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas.
van der Meeren LE; Kluiver J; Rutgers B; Alsagoor Y; Kluin PM; van den Berg A; Visser L
PLoS One; 2019; 14(10):e0223260. PubMed ID: 31603917
[TBL] [Abstract][Full Text] [Related]
12. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
Bouwstra R; He Y; de Boer J; Kooistra H; Cendrowicz E; Fehrmann RSN; Ammatuna E; Zu Eulenburg C; Nijland M; Huls G; Bremer E; van Meerten T
Cancer Immunol Res; 2019 Oct; 7(10):1663-1671. PubMed ID: 31409608
[TBL] [Abstract][Full Text] [Related]
13. ICT1 predicts a poor survival and correlated with cell proliferation in diffuse large B-cell lymphoma.
Xie W; Wu M; Fu T; Li X; Wang Z; Hu Y; Zhu L; Zhang G
Gene; 2017 Sep; 627():255-262. PubMed ID: 28629825
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
Yang JM; Jang JY; Jeon YK; Paik JH
J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
[TBL] [Abstract][Full Text] [Related]
15. Generation and characterization of the Eµ-Irf8 mouse model.
Qiu Z; Holder KN; Lin AP; Myers J; Jiang S; Gorena KM; Kinney MC; Aguiar RCT
Cancer Genet; 2020 Jul; 245():6-16. PubMed ID: 32535543
[TBL] [Abstract][Full Text] [Related]
16. IRF8-mutant B cell lymphoma evades immunity through a CD74-dependent deregulation of antigen processing and presentation in MHC CII complexes.
Qiu Z; Khalife J; Lin AP; Ethiraj P; Jaafar C; Chiou L; Huelgas-Morales G; Aslam S; Arya S; Gupta YK; Dahia PLM; Aguiar RCT
bioRxiv; 2023 Oct; ():. PubMed ID: 37873241
[TBL] [Abstract][Full Text] [Related]
17. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
18. [Significance of microRNA-146b-5p in diffuse large B-cell lymphoma and its relationship with risk assessment].
Cao QW; Li HY; Yao XX; Wang JF
Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1010-4. PubMed ID: 23363792
[TBL] [Abstract][Full Text] [Related]
19. Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma.
Jiang L; Sun Y; Wang J; He Q; Chen X; Lan X; Chen J; Dou QP; Shi X; Liu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):453. PubMed ID: 31694672
[TBL] [Abstract][Full Text] [Related]
20. The tumor suppressive role of inhibin βA in diffuse large B-cell lymphoma.
Jiang L; Si T; Yu M; Zeng X; Morse HC; Lu Y; Ouyang G; Zhou JX
Leuk Lymphoma; 2018 May; 59(5):1202-1212. PubMed ID: 28877610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
